NIH Director Jay Bhattacharya offered an explanation for the cancellation of mRNA vaccine contracts that didn't align with ...

Q1 2025 Management View CEO Matthew Gline described the quarter as "relatively quiet" ahead of an "exciting, busy fall," ...

Discover key insights from Roivant Sciences' Q1 2025 earnings call, including brepocitinib DM data milestones, financial strength, and strategic ...

A regimen involving the company’s shot failed a Phase 3 trial “by a hair,” an executive said, leading the company to believe ...

IO Biotech’s cancer vaccine has “narrowly” failed to beat Merck's blockbuster oncology drug Keytruda in a phase 3 melanoma ...

IO Biotech (IOBT) stock rallies as cancer vaccine, Cylembio, with Merck's (MRK) Keytruda outperforms in a late-stage trial ...

Shares of several biotech firms fell in premarket trading Monday after reports that ousted U.S. Food and Drug Administration ...

The recent announcement of RFK Jr.’s termination of mRNA vaccine contracts is the latest effort to undermine this promising ...

HHS Secretary Robert F Kennedy Jr has canceled nearly $500 million in grants and contracts meant to support mRNA vaccine development.

Are women somehow missing from the future of innovation? New research suggests that gender bias may be quietly shaping the ...